Azithromycin targets the CD27 pathway to modulate CD27hi T-lymphocyte expansion and type-1 effector phenotype.

Saved in:
Bibliographic Details
Title: Azithromycin targets the CD27 pathway to modulate CD27hi T-lymphocyte expansion and type-1 effector phenotype.
Authors: Ansari AW; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.; Dermatology Institute, Interim Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar., Jayakumar MN; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates., Ahmad F; Dermatology Institute, Interim Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar., Venkatachalam T; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates., Salameh L; Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates., Unnikannan H; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates., Raheed T; Dermatology Institute, Interim Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar., Mohammed AK; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates., Mahboub B; Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates., Al-Ramadi BK; Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.; Zayed Center for Health Sciences, United Arab Emirates University (UAEU), Al Ain, United Arab Emirates.; ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Al Ain, United Arab Emirates., Hamid Q; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Meakins-Christie Laboratories, Faculty of Medicine, McGill University, Montreal, QC, Canada., Steinhoff M; Dermatology Institute, Interim Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.; Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.; Weill Cornell Medicine-Qatar, Doha, Qatar.; College of Medicine, Qatar University, Doha, Qatar.; College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar., Hamoudi R; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Biomedically Informed Artificial Intelligence Laboratory (BIMAI-Lab), University of Sharjah, Sharjah, United Arab Emirates.; ASPIRE Precision Medicine Research Institute Abu Dhabi, University of Sharjah, Sharjah, United Arab Emirates.
Source: Frontiers in immunology [Front Immunol] 2024 Aug 15; Vol. 15, pp. 1447625. Date of Electronic Publication: 2024 Aug 15 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2024.1447625